See more : Text S.A. (LCHTF) Income Statement Analysis – Financial Results
Complete financial analysis of ReWalk Robotics Ltd. (RWLK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ReWalk Robotics Ltd., a leading company in the Medical – Devices industry within the Healthcare sector.
- COSCO SHIPPING Energy Transportation Co., Ltd. (1138.HK) Income Statement Analysis – Financial Results
- Challani Capital Ltd (CHALLANI.BO) Income Statement Analysis – Financial Results
- Okuwa Co., Ltd. (8217.T) Income Statement Analysis – Financial Results
- U-Haul Holding Company (UHAL-B) Income Statement Analysis – Financial Results
- Titan Logix Corp. (TPCFF) Income Statement Analysis – Financial Results
ReWalk Robotics Ltd. (RWLK)
About ReWalk Robotics Ltd.
ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions in the United States, Europe, the Asia-Pacific, and Africa. The company offers ReWalk Personal and ReWalk Rehabilitation for spinal cord injuries and everyday use by paraplegic individuals at home and in communities; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke in the clinical rehabilitation environment; and MyoCycle and MediTouch tutor movement biofeedback devices for use at home or in clinic. It markets and sells its products directly to third party payers; institutions, including rehabilitation centers; and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Ilit, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 13.85M | 5.51M | 5.97M | 4.39M | 4.87M | 6.55M | 7.75M | 5.87M |
| Cost of Revenue | 9.40M | 3.61M | 3.06M | 2.20M | 2.15M | 3.72M | 4.65M | 5.13M |
| Gross Profit | 4.45M | 1.91M | 2.90M | 2.19M | 2.73M | 2.83M | 3.10M | 736.00K |
| Gross Profit Ratio | 32.14% | 34.57% | 48.66% | 49.83% | 55.94% | 43.16% | 40.00% | 12.54% |
| Research & Development | 4.15M | 4.03M | 2.94M | 3.46M | 5.35M | 7.35M | 6.04M | 9.03M |
| General & Administrative | 10.00M | 7.13M | 5.63M | 4.98M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 13.92M | 9.84M | 6.99M | 5.75M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 23.92M | 16.98M | 12.62M | 10.73M | 11.43M | 14.69M | 19.05M | 22.15M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 28.07M | 21.01M | 15.56M | 14.19M | 16.77M | 22.04M | 25.09M | 31.18M |
| Cost & Expenses | 37.47M | 24.61M | 18.62M | 16.40M | 18.92M | 25.76M | 29.75M | 36.31M |
| Interest Income | 1.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.00 |
| Interest Expense | 20.00K | 22.00K | 25.00K | 907.00K | 1.53M | 2.42M | 2.48M | 2.01M |
| Depreciation & Amortization | 1.85M | 202.00K | 266.00K | 285.00K | 321.00K | 463.00K | 642.00K | 696.00K |
| EBITDA | -21.77M | -18.90M | -12.39M | -11.73M | -13.72M | -18.79M | -21.48M | -29.79M |
| EBITDA Ratio | -157.10% | -343.35% | -208.30% | -267.29% | -281.70% | -286.49% | -275.38% | -506.82% |
| Operating Income | -23.61M | -19.10M | -12.66M | -12.00M | -14.05M | -19.21M | -21.99M | -30.44M |
| Operating Income Ratio | -170.43% | -346.62% | -212.12% | -273.25% | -288.28% | -293.57% | -283.66% | -518.67% |
| Total Other Income/Expenses | 1.47M | 0.00 | 13.00K | -921.00K | -1.50M | -2.47M | -2.61M | -2.06M |
| Income Before Tax | -22.15M | -19.10M | -12.64M | -12.93M | -15.54M | -21.68M | -24.60M | -32.50M |
| Income Before Tax Ratio | -159.85% | -346.62% | -211.90% | -294.22% | -318.98% | -331.25% | -317.27% | -553.76% |
| Income Tax Expense | -12.00K | 467.00K | 94.00K | 51.00K | 7.00K | -5.00K | 119.00K | 3.00K |
| Net Income | -22.13M | -19.57M | -12.74M | -12.98M | -15.55M | -21.68M | -24.72M | -32.50M |
| Net Income Ratio | -159.76% | -355.09% | -213.48% | -295.38% | -319.13% | -331.17% | -318.81% | -553.81% |
| EPS | -2.59 | -2.20 | -1.86 | -5.74 | -18.90 | -103.04 | -213.98 | -431.63 |
| EPS Diluted | -2.59 | -2.20 | -1.86 | -5.74 | -18.90 | -103.04 | -213.98 | -431.63 |
| Weighted Avg Shares Out | 8.53M | 8.91M | 6.85M | 2.25M | 823.33K | 210.36K | 115.51K | 75.30K |
| Weighted Avg Shares Out (Dil) | 8.53M | 8.91M | 6.85M | 2.25M | 823.33K | 210.36K | 115.51K | 75.30K |
VA STAND Act introduced in the United States Senate
4 Must-Buy Efficient Stocks to Increase Your Portfolio Returns
Lifeward Announces Reverse Share Split
ReStore Exo-Suit Publications Demonstrate Improved Walking Outcomes Versus Conventional Stroke Therapy
Lifeward announces the Centers for Medicare & Medicaid Services (“CMS”) is deferring its final decision on the payment rate for personal exoskeletons so that more recent claims information on the current, more advanced ReWalk Personal Exoskeleton may be considered
ReWalk Robotics (LFWD) Reports Q4 Loss, Misses Revenue Estimates
Lifeward Reports Fourth Quarter and Full Year 2023 Financial Results
Lifeward to Report Fourth Quarter and Fiscal Year-End 2023 Financial Results on February 27, 2024
ReWalk Robotics Transforms Company Identity, Rebrands as Lifeward
7 ‘AgeTech' Stocks to Profit From the Booming Longevity Market
Source: https://incomestatements.info
Category: Stock Reports